Glycodelin in ovarian serous carcinoma: Association with differentiation and survival

Cancer Research

Volumn 63, Issue 19, 2003, Pages 6258-6264

  Mandelin, Erik ^a   Lassus, Heini ^a   Seppälä, Markku ^a   Leminen, Arto ^a   Gustafsson, Jan Åke ^b   Cheng, Guojun ^b   Bützow, Ralf ^a   Koistinen, Riitta ^a,c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Thermo Fisher Scientific Oy   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; LIPOCALIN; PLACENTA PROTEIN 14; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVARY SEROUS CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SURVIVAL TIME; TUMOR CELL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; CELL DIFFERENTIATION; CYSTADENOCARCINOMA, SEROUS; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREGNANCY PROTEINS; PROGNOSIS; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 0141919566     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Schilder, R. J., Boente, M. P., Corn, B. W., Lanciano, R. M., Young, R. C., and Ozols, R. F. The management of early ovarian cancer. Oncology, 9: 171-182, 1995.
2. Baekelandt, M., Holm, R., Nesland, J. M., Trope, C. G., and Kristensen, G. B. Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer. J. Clin. Oncol., 18: 3775-3781, 2000.
3. Toy, E. P., Chambers, J. T., Kacinski, B. M., Flick, M. B., and Chambers, S. K. The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma. Gynecol. Oncol., 80: 194-200, 2001.
4. Kim, H., Scorilas, A., Katsaros, D., Yousef, G. M., Massobdo, M., Fracchioli, S., Piccinno, R., Gordini, G., and Diamandis, E. P. Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br. J. Cancer, 84: 643-650, 2001.
5. Simojoki, M., Santala, M., Risteli, J., and Kauppila, A. Carboxyterminal telopeptide of type I collagen (ICTP) in predicting prognosis in epithelial ovarian cancer. Gynecol. Oncol., 82: 110-115, 2001.
6. Vartiainen, J., Lehtovirta, P., Finne, P., Stenman, U. H., and Alfthan, H. Preoperative serum concentration of HCGP as a prognostic factor in ovarian cancer. Int. J. Cancer, 95: 313-316, 2001.
7. Denkert, C., Kobel, M., Pest, S., Koch, I., Berger, S., Schwabe, M., Siegert, A., Reles, A., Klosterhalfen, B., and Hauptmann, S. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am. J. Pathol., 160: 893-903, 2002.
8. Cooper, B. C., Sood, A. K., Davis, C. S., Ritchie, J. M., Sorosky, J. I., Anderson, B., and Buller, R. E. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet. Gynecol., 100: 59-64, 2002.
9. Stenman, U. H. Tumor-associated trypsin inhibitor. Clin. Chem., 48: 1206-1209, 2002.
10. Hogdall, E. V., Hogdall, C. K., Christensen, L., Glud, E., Blaakaer, J., Bock, J. E., Vuust, J., Norgaard-Pedersen, B., and Kjaer, S. K. Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients. Anticancer Res., 22: 1859-1864, 2002.
11. Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J., Fusaro, V. A., Steinberg, S. M., Mills, G. B., Simone, C., Fishman, D. A., Kohn, E. C., and Liotta, L. A. Use of protcomic patterns in serum to identify ovarian cancer. Lancet, 359: 572-577, 2002.
12. Daly, M. B., and Ozols, R. F. The search for predictive patterns in ovarian cancer: proteomics meets bioinformatics. Cancer Cell, I: 111-112, 2002.
13. Seppälä, M., Taylor, R. N., Koistinen, H., Koistincn, R., and Milgrom, E. Glycodelin: a major lipocalin protein of the reproductive axis with diverse actions in cell recognition and differentiation. Endocr. Rev., 23: 401-430, 2002.
14. Arnold, J. T., Lessey, B. A.. Seppala, M., and Kaufman, D. G. Effect of normal endometrial stroma on growth and differentiation in Ishikawa endometrial adenocarcinoma cells. Cancer Res., 62: 79-88, 2002.
15. Julkunen, M., Koistinen, R., Sjöberg J., Rutanen, E. M., Wahlström, T., and Seppälä, M. Secretory endometrium synthesizes placental protein 14. Endocrinology, 118: 1782-1786, 1986.
16. Arnold, J. T., Kaufman, D. G., Seppala, M., and Lessey, B. A. Endometrial stromal cells regulate epithelial cell growth in vitro: a new co-culture model. Hum. Reprod., 16: 836-845, 2001.
17. Gao, J., Mazella, J., Seppala, M., and Tseng, L. Ligand activated hPR modulates the glycodelin promoter activity through the Sp1 sites in human endometrial adenocarcinoma cells. Mol. Cell. Endocrinol., 176: 97-102, 2001.
18. Vaisse, C., Atger, M., Potier, B., and Milgrom, E. Human placental protein 14 gene: sequence and characterization of a short duplication. DNA Cell Biol., 9: 401-413, 1990.
19. Kämäräinen, M., Seppälä, M., Virtanen, I., and Andersson, L. C. Expression of glycodelin in MCF-7 breast cancer cells induces differentiation into organized acinar epithelium. Lab. Investig., 77: 565-573, 1997.
20. Morris, H. R., Dell, A., Easton, R. L., Panico, M., Koistinen, H., Koistinen, R., Oehninger, S., Patankar, M. S., Seppälä, M., and Clark, G. F. Gender-specific glycosylation of human glycodelin affects its contraceptive activity. J. Biol. Chem., 271: 32159-32167, 1996.
21. Bolton, A. E., Pockley, A. G., Clough, K. J., Mowles, E. A., Stoker, R. J., Westwood, O. M., and Chapman, M. G. Identification of placental protein 14 as an immunosuppressive factor in human reproduction. Lancet, 1: 593-595, 1987.
22. Okamoto, N., Uchida, A., Takakura, K., Kariya, Y., Kanzaki, H., Riittinen, L., Koistinen, R., Seppala, M., and Mori, T. Suppression by human placental protein 14 of natural killer cell activity. Am. J. Reprod. Immunol., 26: 137-142, 1991.
23. Rachmilewitz, J., Riely, G. J., Huang, J. H., Chen, A., and Tykocinski, M. L. A rheostatic mechanism for T-cell inhibition based on elevation of activation thresholds. Blood, 98: 3727-3732, 2001.
24. Riittinen, L. Serous ovarian cyst fluids contain high levels of endometrial placental protein 14. Tumour Biol., 13: 175-179, 1992.
25. Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., and Kallioniemi, O. P. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med., 4: 844-847, 1998.
26. Kämäräinen, M., Leivo, I., Koistinen, R., Julkunen, M., Karvonen, U., Rutanen, E. M., and Seppälä, M. Normal human ovary and ovarian tumors express glycodelin, a glycoprotcin with immunosuppressive and contraceptive properties. Am. J. Pathol., 148: 1435-1443, 1996.
27. Mote, P. A., Johnston, J. F., Manninen, T., Tuohimaa, P., and Clarke, C. L. Detection of progesterone receptor forms A and B by immunohistochemical analysis. J. Clin. Pathol., 54: 624-630, 2001.
28. Tse, J. Y., Chiu, P. C., Lee, K. F., Seppala, M., Koistinen, H., Koistinen, R., Yao, Y. Q., and Yeung, W. S. The synthesis and fate of glycodelin in human ovary during folliculogenesis. Mol. Hum. Reprod., 8: 142-148, 2002.
29. Song, M., Ramaswamy, S., Ramachandran, S., Flowers, L. C., Horowitz, I. R., Rock, J. A., and Parthasarathy, S. Angiogenic role for glycodelin in tumorigencsis. Proc. Natl. Acad. Sci. USA, 98: 9265-9270, 2001.
30. Zhou, H. M., Ramachandran, S., Kim, J. G., Raynor, D. B., Rock, J. A., and Parthasarathy, S. Implications in the management of pregnancy: II. Low levels of gene expression but enhanced uptake and accumulalion of umbilical cord glycodelin. Fertil. Steril., 73: 843-847, 2000.
31. Capo-Chichi, C. D., Smith, E. R., Yang, D. H., Roland, I. H., Vanderveer, L., Cohen, C., Hamilton, T. C., Godwin, A. K., and Xu, X. X. Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis. Cancer (Phila.), 95: 1802-1815, 2002.
32. Roskelley, C. D., and Bissell, M. J. The dominance of the microenvironment in breast and ovarian cancer. Semin. Cancer Biol., 12: 97-104, 2002.
33. Pere, H., Tapper, J., Seppala, M., Knuutila, S., and Butzow, R. Genomic alterations in fallopian tube carcinoma: comparison to serous uterine and ovarian carcinomas reveals similarity suggesting likeness in molecular pathogenesis. Cancer Res., 58: 4274-4276, 1998.
34. Devlin, J., Elder, P. A., Gabra, H., Steel, C. M., and Knowles, M. A. High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci. Br. J. Cancer, 73: 420-423, 1996.
35. Van Cong, N., Vaisse, C., Gross, M. S., Slim, R., Milgrom, E., and Bernheim, A. The human placental protein 14 (PP14) gene is localized on chromosome 9q34. Hum. Genet., 86: 515-518, 1991.
36. McDonnell, D. P., and Goldman, M. E. RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism. J. Biol. Chem., 269: 11945-11949, 1994.
37. Vegeto, E., Shahbaz, M. M., Wen, D. X., Goldman, M. E., O'Malley, B. W., and McDonnell, D. P. Human progesterone receptor A fonn is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol. Endocrinol., 7: 1244-1255, 1993.